Tag Archives: CLLS

Best Value Stocks To Own Right Now

Omnicell, Inc. (NASDAQ:OMCL) EVP Jorge R. Taborga sold 19,796 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $83.86, for a total value of $1,660,092.56. Following the sale, the executive vice president now directly owns 36,156 shares in the company, valued at approximately $3,032,042.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

NASDAQ:OMCL traded down $0.03 during trading hours on Tuesday, hitting $83.95. 274,200 shares of the stock traded hands, compared to its average volume of 343,503. The company has a quick ratio of 1.45, a current ratio of 1.94 and a debt-to-equity ratio of 0.20. Omnicell, Inc. has a fifty-two week low of $41.59 and a fifty-two week high of $86.87. The company has a market cap of $3.29 billion, a P/E ratio of 54.87, a price-to-earnings-growth ratio of 4.01 and a beta of 1.18.

Best Value Stocks To Own Right Now: ManpowerGroup(MAN)

Advisors’ Opinion:

  • [By Shane Hupp]

    DnB Asset Management AS grew its stake in shares of ManpowerGroup Inc. (NYSE:MAN) by 18.3% in the second quarter, according to its most recent filing with the SEC. The fund owned 29,058 shares of the business services provider’s stock after acquiring an additional 4,500 shares during the period. DnB Asset Management AS’s holdings in ManpowerGroup were worth $2,501,000 at the end of the most recent reporting period.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on ManpowerGroup (MAN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    TRADEMARK VIOLATION WARNING: “ManpowerGroup (MAN) Posts Quarterly Earnings Results, Beats Estimates By $0.09 EPS” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/3373626/manpowergroup-man-posts-quarterly-earnings-results-beats-estimates-by-0-09-eps.html.

  • [By Shane Hupp]

    Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lowered its stake in shares of ManpowerGroup (NYSE:MAN) by 12.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,463 shares of the business services provider’s stock after selling 1,109 shares during the quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in ManpowerGroup were worth $859,000 at the end of the most recent reporting period.

Best Value Stocks To Own Right Now: Horizon Global Corporation(HZN)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Horizon Global (HZN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Horizon Global (HZN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Horizon Global (NYSE:HZN) had its price target upped by research analysts at Roth Capital from $6.50 to $7.50 in a research note issued to investors on Friday. The brokerage currently has a “neutral” rating on the stock. Roth Capital’s target price indicates a potential upside of 20.97% from the stock’s current price.

  • [By Brian Feroldi]

    Horizon Global (NYSE:HZN) reported its second-quarter results on Aug. 7th. Investors had already been provided with a sneak peek at the towing and trailering company’s results in mid-July after management announced that it was expanding its ability to borrow by $50 million. The company’s second-quarter results were largely in line with those updated projections, and management reaffirmed that its turnaround remains on track. However, the year-over-year numbers did not look pretty.

  • [By Lisa Levin]

     

    Losers
    Heat Biologics, Inc. (NASDAQ: HTBX) shares tumbled 48.59 percent to close at $1.275 on Thursday after the company priced its $18,000,000 public offering.
    InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) fell 38.77 percent to close at $8.26 on Thursday.
    Check-Cap Ltd. (NASDAQ: CHEK) shares tumbled 27.43 percent to close at $8.81.
    Achaogen, Inc. (NASDAQ: AKAO) dropped 24.76 percent to close at $11.06 in reaction to a disappointing update from an FDA AdCom panel. The FDA panel voted favorably for the company's Plazcomicin for treatment of adults with complicated urinary tract infections, but also voted against the therapy to be used as a treatment for bloodstream infections.
    Anika Therapeutics, Inc. (NASDAQ: ANIK) shares declined 24.68 percent to close at $34.80 after the company posted downbeat quarterly results.
    LSC Communications, Inc. (NASDAQ: LKSD) shares fell 24.22 percent to close at $12.64 following wider-than-expected Q1 loss.
    Cardinal Health, Inc. (NYSE: CAH) fell 21.42 percent to close at $50.80 following downbeat quarterly profit.
    Horizon Global Corporation (NYSE: HZN) dropped 20.42 percent to close at $6.00 following downbeat quarterly earnings.
    Hornbeck Offshore Services, Inc. (NYSE: HOS) slipped 20.11 percent to close at $2.90 following wider-than-expected Q1 loss.
    Esperion Therapeutics, Inc. (NASDAQ: ESPR) fell 19.28 percent to close at $36.93. Esperion Therapeutics stock lost roughly a third of its value Wednesday after the company reported mixed Phase III results for its leading drug candidate, bempedoic acid. JP Morgan downgraded Esperion Therapeutics from Neutral to Underweight.
    Laredo Petroleum, Inc. (NYSE: LPI) declined 17.77 percent to close at $8.98 after the company reported weaker-than-expected Q1 earnings.
    The Habit Restaurants, Inc. (NASDAQ: HABT) dipped 16.1 percent to close at $8.60 after the company reported downbeat quarterly results.
    Arcadia Biosciences, Inc. (N

Best Value Stocks To Own Right Now: region(XIV)

Advisors’ Opinion:

  • [By Money Morning News Team]

    This led some traders to purchase leveraged ETFs that move inverse to the VIX, like the VelocityShares Daily Inv VIX Short Term (Nasdaq: XIV).

    The VIX is a derivative of the broad S&P 500, and the XIV is a derivative of that derivative.

Best Value Stocks To Own Right Now: MYR Group Inc.(MYRG)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Euro Tech Holdings Company Limited (NASDAQ: CLWT) shares jumped 155.56 percent to close at $5.75 on Thursday.
    Inspire Medical Systems, Inc. (NYSE: INSP) shares gained 56.12 percent to close at $24.98. Inspire Medical went public Thursday on the New York Stock Exchange. The company issued 6.75 million shares priced at $16 each.
    Presbia PLC (NASDAQ: LENS) shares rose 53.02 percent to close at $3.55.
    Integrated Media Technology Limited (NASDAQ: IMTE) shares rose 46.29 percent to close at $32.11. The nano-cap low-float stock skyrocketed over 1,300 percent on Wednesday on no company specific news which would support the surge. The move higher is consistent with what was seen in other low-float stocks over the past few months.
    Technical Communications Corporation (NASDAQ: TCCO) climbed 27.78 percent to close at $5.75.
    STAAR Surgical Company (NASDAQ: STAA) shares gained 26.27 percent to close at $21.15 after reporting upbeat Q1 results.
    Sharing Economy International Inc. (NASDAQ: SEII) shares jumped 22.16 percent to close at $4.30 on Thursday after gaining 9.32 percent on Wednesday.
    China Advanced Construction Materials Group, Inc. (NASDAQ: CADC) rose 20.45 percent to close at $2.65 on Thursday.
    YRC Worldwide Inc. (NASDAQ: YRCW) surged 18.36 percent to close at $9.99 following upbeat quarterly earnings.
    MYR Group Inc. (NASDAQ: MYRG) jumped 17.68 percent to close at $35.74 after the company posted strong Q1 earnings.
    Xspand Products Lab Inc (NASDAQ: XSPL) jumped 17.4 percent to close at $5.87. Xspand Products priced its IPO at $5 per share.
    Coherus BioSciences, Inc. (NASDAQ: CHRS) shares rose 17.32 percent to close at $14.90. Coherus BioSciences reported resubmission of BLA for CHS-1701.
    Rudolph Technologies, Inc. (NASDAQ: RTEC) shares gained 17.17 percent to close at $31.05 following upbeat quarterly earnings.
    The Meet Group, Inc. (NASDAQ: MEET) gained 16.02 percent to close at $2.68 following Q1 earnings.
    Ca
  • [By Logan Wallace]

    Get a free copy of the Zacks research report on MYR Group (MYRG)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Lisa Levin] Gainers
    Euro Tech Holdings Company Limited (NASDAQ: CLWT) surged 73.3 percent to $3.90.
    Integrated Media Technology Limited (NASDAQ: IMTE) shares gained 51 percent to $33.1365. The nano-cap low-float stock skyrocketed over 1,300 percent on Wednesday on no company specific news which would support the surge. The move higher is consistent with what was seen in other low-float stocks over the past few months.
    Monaker Group, Inc. (NASDAQ: MKGI) shares jumped 34 percent to $3.00.
    Sharing Economy International Inc. (NASDAQ: SEII) shares rose 28.2 percent to $4.51 after gaining 9.32 percent on Wednesday.
    STAAR Surgical Company (NASDAQ: STAA) shares jumped 27.8 percent to $21.40 after reporting upbeat Q1 results.
    Boxlight Corporation (NASDAQ: BOXL) rose 20.5 percent to $8.920 after climbing 107.87 percent on Wednesday.
    Xspand Products Lab Inc (NASDAQ: XSPL) gained 19.5 percent to $ 5.97. Xspand Products priced its IPO at $5 per share.
    YRC Worldwide Inc. (NASDAQ: YRCW) rose 18.9 percent to $10.035 following upbeat quarterly earnings.
    ENDRA Life Sciences Inc. (NASDAQ: NDRA) gained 18.3 percent to $3.0177. ENDRA Life Sciences is expected to report Q1 results on May 15.
    MYR Group Inc. (NASDAQ: MYRG) rose 18.1 percent to $35.85 after the company posted strong Q1 earnings.
    Rudolph Technologies, Inc. (NASDAQ: RTEC) shares jumped 16 percent to $30.75 following upbeat quarterly earnings.
    TTM Technologies, Inc. (NASDAQ: TTMI) gained 13.7 percent to $16.53 after reporting Q1 results.
    Insight Enterprises, Inc. (NASDAQ: NSIT) shares surged 12 percent to $40.06 following better-than-expected Q1 earnings.
    TreeHouse Foods, Inc. (NYSE: THS) rose 11.8 percent to $40.93 following Q1 results.
    Engility Holdings, Inc. (NYSE: EGL) surged 11.2 percent to $27.36. Engility reported upbeat quarterly earnings.
    Synalloy Corporation (NASDAQ: SYNL) rose 10.7 percent to $19.10 following Q1 results.
    Logitech International S.A. (NASDAQ: LOGI)
  • [By Max Byerly]

    News headlines about MYR Group (NASDAQ:MYRG) have been trending somewhat positive on Thursday, Accern reports. Accern scores the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. MYR Group earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned media coverage about the utilities provider an impact score of 46.210188030524 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

  • [By Motley Fool Transcribers]

    MYR Group Inc  (NASDAQ:MYRG)Q4 2018 Earnings Conference CallMarch 07, 2019, 10:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on MYR Group (MYRG)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Best Value Stocks To Own Right Now: Cellectis S.A.(CLLS)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Shares of Cellectis SA (NASDAQ:CLLS) have earned an average recommendation of “Hold” from the nine research firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $42.00.

  • [By Ethan Ryder]

    Media headlines about Cellectis (NASDAQ:CLLS) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cellectis earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 47.0875412676142 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Hot Low Price Stocks To Own Right Now

An extended bout of low prices and tepid wage growth are showing signs of ending and that has government-bond investors bracing for a new inflation regime.

Rising inflation is anathema to bonds because it can erode the security’s fixed value, which is a notable headwind for longer-dated government paper.

Contributing to the anticipation of higher inflation are climbing commodity prices, improving global growth and lingering fears that tightening labor markets will eventually translate into higher wage gains. That has stoked fears that a pick up in what has otherwise been stubbornly low inflation will blindside Treasury buyers.

Hot Low Price Stocks To Own Right Now: Liberty Broadband Corporation(LBRDK)

Advisors’ Opinion:

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Liberty Broadband Corp Series C (LBRDK)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Jim Royal]

    It’s been more than five years since Malone’s Liberty empire took a 27.3% stake in the once-beleaguered cable company for $2.6 billion. Following the deal’s announcement, the stock hit $100 a share, which seems like a steal at today’s prices. Currently Malone’s Liberty Broadband (NASDAQ:LBRDA)(NASDAQ:LBRDK) tracking stock owns a 23.3% stake worth about $16.6 billion.

  • [By Ethan Ryder]

    Media headlines about Liberty Broadband Corp Series C (NASDAQ:LBRDK) have trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Liberty Broadband Corp Series C earned a coverage optimism score of 0.14 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.2592060171908 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Hot Low Price Stocks To Own Right Now: The Kraft Heinz Company(KHC)

Advisors’ Opinion:

  • [By Lee Jackson]

    This leading global food company was formed almost three years ago by the merger of H.J. Heinz and Kraft Foods Group. Kraft Heinz Co. (NYSE: KHC) had $29 billion of annual revenues generated by well-known brands such as Kraft, Heinz, Oscar Meyer and Maxwell House.

  • [By ]

    During his recent, odd earnings call, Musk referred to business moats as “lame,” saying that if “your only defense against invading armies is a moat, you will not last long.” For those just joining us, in business a moat is a competitive advantage created by ownership of a strong brand name that discourages entry into the firm’s markets. Buffett has made a career of investing in firms with “moats” — think Apple, Coca-Cola (KO) , Kraft Heinz (KHC) , Burlington Northern Santa Fe or See’s Candy.

  • [By Logan Wallace]

    TRADEMARK VIOLATION WARNING: “19,243 Shares in Kraft Heinz Co (KHC) Acquired by Advisory Resource Group” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/4205319/19243-shares-in-kraft-heinz-co-khc-acquired-by-advisory-resource-group.html.

  • [By Ethan Ryder]

    TRADEMARK VIOLATION NOTICE: “Commonwealth Equity Services LLC Decreases Holdings in Kraft Heinz Co (KHC)” was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/4195539/commonwealth-equity-services-llc-decreases-holdings-in-kraft-heinz-co-khc.html.

  • [By ]

    Buffett’s biggest losers have been Kraft Heinz Co. (KHC) , down 30%; Procter & Gamble Co. (PG) , down 21%; Southwest Airlines Co. (LUV) , down 20%; American Airlines Group Inc. (AAL) , down 19%; and Charter Communications Inc (CHTR) , down 18%. Maybe on those grounds he should reconsider his remarks in February when he said he was open to buying an entire airline.

  • [By Isaac Pino, CPA]

    If you’re an investor in consumer goods giant Unilever (NYSE:UN), odds are you followed the takeover bid from Kraft Heinz (NASDAQ: KHC) closely in 2017. Ultimately, it fell through, with Unilever’s management rebutting that it was better off on its own. There was some mustard left on the face of Kraft Heinz, but major shareholder Warren Buffett claimed there was potentially a misunderstanding of the nature of the offer. It was not intended to be a hostile takeover, he said, but it could have been perceived that way by Unilever.

Hot Low Price Stocks To Own Right Now: Industrial Select Sector SPDR ETF (XLI)

Advisors’ Opinion:

  • [By ]

    Shares of the Industrials Select Sector SPDR (NYSE: XLI) returned 28% over the year to mid-February and the sector trades a premium of 22% on its long-term forward multiple.

  • [By Dan Caplinger]

    Nevertheless, some sectors of the market are doing better than others. When it comes to the 11 sectors that the company behind the Select Sector SPDR line of ETFs tracks, the best returns so far have come from Industrials Select Sector SPDR (NYSEMKT:XLI), Energy Select Sector SPDR (NYSEMKT:XLE), and Technology Select Sector SPDR (NYSEMKT:XLK).

  • [By Paul Ausick]

    3M is the second-largest holding in the Industrial Select Sector SPDR ETF (NYSEArca: XLI) at 5.29%. Boeing is the largest with a 7.93% share of the fund, but the fund’s increase for the year is 4.7%, well below the Dow index. Virtually all of last week’s increase in the fund came on Monday.

  • [By Todd Shriber, ETF Professor]

    The broader industrial sector has faced challenges this year, but the recent performance of the Industrial Select Sector SPDR (NYSE: XLI) indicates some investors are turning positive on the group. XLI, the largest industrial exchange traded fund, is up 5 percent over the past week.

  • [By Steve Symington]

    Tech stocks set the pace, with the Technology Select Sector SPDR Fund (NYSEMKT:XLK) adding 2.2%. Industrial names posted more modest gains, with the Industrial Select Sector SPDR Fund (NYSEMKT:XLI) rising 0.9%.

  • [By Steve Symington]

    Industrials stocks led the way lower today, with the Industrial Select Sector SPDR Fund (NYSEMKT:XLI) falling 1.1%. But tech stocks held up surprisingly well on the heels of yesterday’s losses, with the Technology Select Sector SPDR Fund (NYSEMKT:XLK) wavering between positive and negative territory before closing down just 0.1%.

Hot Low Price Stocks To Own Right Now: Cellectis S.A.(CLLS)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Media headlines about Cellectis (NASDAQ:CLLS) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cellectis earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 47.0875412676142 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

  • [By Stephan Byrd]

    Shares of Cellectis SA (NASDAQ:CLLS) have earned an average recommendation of “Hold” from the nine research firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $42.00.

Top 10 Casino Stocks To Watch Right Now

1. Topsy-turvy stocks: The volatility of the past few trading days could continue into Wednesday.

U.S. stock futures are moving down, indicating all the major indexes could drop by about 1% at the open.

Meanwhile, European markets are in recovery mode after falling by 2% to 3% on Tuesday.

News that German Chancellor Angela Merkel had struck a deal with her center-left rivals to form a coalition government could be supporting market sentiment. The breakthrough follows four months of uncertainty.

Asian markets ended with mixed results. The Shanghai Composite dropped by 1.8% on Wednesday. It’s lost as much as 8% since a recent peak in late January.

On Tuesday, after a gut-wrenching drop in the morning, U.S. markets staged a big recovery. The Dow Jones industrial average closed with a 2.3% gain, while the S&P 500 rose 1.7% and the Nasdaq surged by 2.1%.

2. Wynn steps down: Steve Wynn has stepped down as CEO of Wynn Resorts after allegations of sexual misconduct piled pressure on the billionaire casino mogul and sent the company’s stock tumbling.

Top 10 Casino Stocks To Watch Right Now: TEGNA Inc.(TGNA)

Advisors’ Opinion:

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Tuesday was Tegna Inc. (NYSE: TGNA) which traded down 6.3% at $22.03. The stocks 52-week range is $17.91 to $26.65. Volume was 8.6 million versus the daily average of 2.2 million shares.

  • [By Paul Ausick]

    Tegna Inc. (NYSE: TGNA) dropped 2.5% Monday to post a new 52-week low of $14.32 after closing at $14.68 on Friday. The stock’s 52-week high is $26.65. Volume was about 7.1 million, approaching double the daily average of around 3.8 million shares. The company had no specific news, but is still feeling the effects of its spin-off of Cars.com.

Top 10 Casino Stocks To Watch Right Now: M.D.C. Holdings, Inc.(MDC)

Advisors’ Opinion:

  • [By Stephan Byrd]

    MDC (NYSE:MDC)‘s stock had its “buy” rating reiterated by equities research analysts at Raymond James in a report released on Tuesday, MarketBeat reports. They presently have a $39.00 target price on the construction company’s stock, up from their previous target price of $35.00. Raymond James’ target price indicates a potential upside of 26.09% from the company’s current price.

  • [By Lisa Levin]

    Cyclical consumer goods & services sector was the top gainer in the US market on Tuesday. Top gainers in the sector included M.D.C. Holdings, Inc. (NYSE: MDC), Delta Apparel, Inc. (NYSE: DLA), and Commercial Vehicle Group, Inc. (NASDAQ: CVGI).

Top 10 Casino Stocks To Watch Right Now: Guidewire Software, Inc.(GWRE)

Advisors’ Opinion:

  • [By Monica Gerson]

    Guidewire Software Inc (NYSE: GWRE) is estimated to post its quarterly earnings at $0.06 per share on revenue of $92.43 million.

    Analogic Corporation (NASDAQ: ALOG) is projected to post its quarterly earnings at $0.88 per share on revenue of $127.30 million.

  • [By Peter Graham]

    A long term performance chart shows Ebix Inc actually performing well since the end of 2014 while mid cap peer Guidewire Software Inc (NYSE: GWRE) has been outperforming over a longer period of time and small cap Benefitfocus Inc (NASDAQ: BNFT) has underperformed:

  • [By Stephan Byrd]

    TRADEMARK VIOLATION NOTICE: “Insider Selling: Guidewire Software (GWRE) Insider Sells 209 Shares of Stock” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/3365485/insider-selling-guidewire-software-gwre-insider-sells-209-shares-of-stock.html.

Top 10 Casino Stocks To Watch Right Now: Cellectis S.A.(CLLS)

Advisors’ Opinion:

  • [By Jim Robertson]

    Yesterday, small cap clinical-stage biopharmaceutical stock Cellectis SA (NASDAQ: CLLS) reported that they had received notice fromFDA that a clinical hold was placed on both UCART123 ongoing Phase 1 studies -in acute myeloid leukemia (AML) and in blastic plasmacytoid dendritic cell neoplasm (BPDCN). The clinical hold was initiated after Cellectis reported one fatality in the BPDCN clinical trial (ABC study) with the Company now working closelywith the investigators and the FDA in order to resume the trials with an amended protocol including a lowered dosing of UCART123. The FDA has a detailed page about clinical holds which mentions:

  • [By Lisa Levin]

    Cellectis SA (ADR) (NASDAQ: CLLS) shares dropped 20 percent to $25.70 after announcing FDA clinical hold of UCART123 studies.

    Shares of Opiant Pharmaceuticals Inc (NASDAQ: OPNT) were down 10 percent to $35.20. Opiant Pharma named David O'Toole as CFO.

Top 10 Casino Stocks To Watch Right Now: Huntington Ingalls Industries, Inc.(HII)

Advisors’ Opinion:

  • [By Lou Whiteman]

    Huntington Ingalls Industries (NYSE:HII) and Lockheed Martin (NYSE:LMT)are each up about 25% over the past year, though Lockheed is significantly higher valued on both a price-to-earnings and price-to-sales basis. Let’s take a look at the prospects for both companies with an eye toward determining which is a better buy right now.

  • [By Ethan Ryder]

    Advantus Capital Management Inc decreased its holdings in Huntington Ingalls Industries (NYSE:HII) by 17.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,606 shares of the aerospace company’s stock after selling 987 shares during the period. Advantus Capital Management Inc’s holdings in Huntington Ingalls Industries were worth $1,187,000 at the end of the most recent reporting period.

  • [By Paul Ausick]

    The carriers are being constructed by Huntington Ingalls Industries Inc. (NYSE: HII) at a total acquisition cost of around $55 billion. Work on the carriers provides more than 20,000 jobs at Huntington’s Newport News shipyard.

  • [By Michael A. Robinson]

    On Feb. 16, Huntington Ingalls Industries Inc. (NYSE: HII) snagged a massive $1.43 billion contract to design and build the LPD 29, a San Antonio-class amphibious transport dock.

  • [By Lou Whiteman]

    Shares of Huntington Ingalls Industries (NYSE:HII) plunged more than 8% on May 3 after the company reported first quarter earnings that came in well below analyst estimates. The shipbuilder had been climbing steadily higher leading up to earnings season, propelled by increased Pentagon spending and calls from the Trump Administration to dramatically expand the U.S. Navy.

  • [By Ethan Ryder]

    Spectrum Asset Management Inc. NB CA acquired a new stake in Huntington Ingalls Industries (NYSE:HII) in the 1st quarter, according to the company in its most recent filing with the SEC. The firm acquired 3,995 shares of the aerospace company’s stock, valued at approximately $972,000.

Top 10 Casino Stocks To Watch Right Now: TESARO, Inc.(TSRO)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Look out below! Shares of Tesaro (TSRO) have dropped more than 10% this afternoon after AstraZeneca (AZN) released stronger-than-expected Phase 3 trial data on a its ovarian cancer treatment.

    Agence France-Presse/Getty Images

    The Street’sAdam Feuerstein has the details on AstraZeneca’s strong data and its impact on Tesaro:

    AstraZeneca’s (AZN) PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo, according to results from a phase III study presented Tuesday.

    The strong benefit observed with Lynparza as ovarian cancer maintenance therapy exceeded investor expectations and bolsters AstraZeneca against a competing PARP inhibitor from Tesaro (TSRO).

    Feuerstein also notes that AstraZeneca’s data could be good newsClovis Oncology (CLVS), which also had a PARP inhibitor approved recently, if it means that its drug could work as well as Astra’s.

    In February, Leerink cut Tesaro, arguing that the rally in its shares due to a potential takeover had run too far. Will it still be a takeover target?

    Shares of Tesaro have dropped 14% to $148.01 at 3:28 p.m. today, while AstraZeneca has gained 1.1% to $30.41, and Clovis Oncology has jumped 9.8% to$66.55.

    UPDATE:Piper Jaffray’sSteven Breazzano andJoshua Schimmer note that the AstraZeneca data shows that PARPs are “more similar than different.” They explain:

    This afternoon AstraZeneca (covered by PJC analyst Richard Purkiss) reported the detailed results from the SOLO-2 maintenance study of Lynparza in 2L+ ovarian cancer. The detailed data highlights a PFS benefit of 14 months (investigator assessed, and primary endpoint) and 25 months (blinded central review) over placebo, and favorable hazard ratio of 0.30 and 0.25, respectively, confirming our view that the PARP’s are more similar than different. As such, we believe this provides a favorable readth

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Tesaro (TSRO)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Todd Campbell]

    Tesaro’s (NASDAQ:TSRO)ovarian cancer drug, niraparib, will begin competing for prescriptions earlier than expected. Niraparib, which will be sold under the brand name Zejula, notched FDA approval on Monday, more than three months ahead of its June 30 decision date. The early approval setsTesaro up for a fierce battle for market share withAstraZeneca (NYSE:AZN)and Clovis Oncology (NASDAQ:CLVS), both of which market drugs that work similarly to Zejula.

  • [By Ben Levisohn]

    Shares of Tesaro (TSRO) are soaring today after the biotech company reported positive data for its treatment of ovarian cancer over the weekend. Credit Suisse analyst Alethia Young and team contend that “M&A remains in focus” for Tesaro following the data:

    Getty Images

    We are increasing our target price to $122 from $90 as we move to an M&A DCF valuation. We were at ESMO this weekend, and we believe the big takeaway on Tesaro data is that it works broadly in all 2L ovarian populations and safety looks solid. We also think the robustness of this data bodes well from PRIMA and QUADRA but are maintaining our POS here. We have looked at our model and also adjusted durations in first-line. We think Tesaro remains one of the most attractive and de-risked cancer assets in our landscape and the company has been cited in major press sources as a takeout target (Bloomberg, Investor Business Daily).

    We think M&A remains in focus for Tesaro. Our M&A DCF valuations range from $122 to $157 by our model. We have also built models for other cancers like NSCLC, SCLC, prostate, and others where PARP might be impactful. We assume 0% POS for now but we conservatively see at least another $1B in sales from PARP expansion. Tesaro has been cited in the press as a potential M&A target and is a company we frequently hear mentioned as a target from our conversations. We think the demand for late stage oncology assets is high, especially in the PARP space given the potential for activity across a range of tumors. For a large Pharma player who already has an oncology salesforce and large R&D infrastructure we could see SG&A synergies of 50-75% and R&D synergies of 15-30%. In our base case TSRO P&L we model a tax rate of 30% so there could be synergies here as well. Two additional key swing factors which might be included in a CVR are how much expansion from PARP in other cancers and immuno-oncology…

    Ex M&A,

Top 10 Casino Stocks To Watch Right Now: Vince Holding Corp.(VNCE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Gainers

    Pyxis Tankers Inc. (NYSE: PXS) rose 47.48 percent to $$5.56, after the company announced it has entered into a definitive securities purchase agreement with a group of investors, which will result in gross proceeds of $4.8 million.
    Sigma Designs Inc (NASDAQ: SIGM) rose 22.77 percent to $6.88. Silicon Laboratories (NASDAQ: SLAB) announced plans to buy Sigma Designs for $7.05 per share in cash.
    Steadymed Ltd (NASDAQ: STDY) rose 19.35 percent to $3.70, after the company reported that no clinical trials were required for Trevyent and that the FDA had agreed to the pathway for the drug candidate's NDA resubmission.
    Iteris, Inc. (NASDAQ: ITI) rose 15.73 percent to $7.06. Earlier in the week, Zacks Investment Research had upgraded the company from "Sell" to "Hold".
    Science Applications International Corp (NYSE: SAIC) rose 13.71 percent to $85.77 as the company reported better-than-expected earnings for its third quarter.
    Technical Communications Corporation (NASDAQ: TCCO) rose 12.41 percent to $6.07, after having risen sharply in pre-marketing trading.
    Radius Health, Inc. (NASDAQ: RDUS) rose 12.41 percent to $30.81 after the company provided an update on data from the Phase 1 005 clinical study of elacestrant in patients with estrogen receptor positive breast cancer during the 2017 San Antonio Breast Cancer Symposium.
    ForeScout Technologies, Inc. (NASDAQ: FSCT) rose 12.32 percent to $25.80 after the company reported its third quarter financial results.
    Prana Biotechnology Limited (NASDAQ: PRAN) rose 11.36 percent to $3.43, as the company announced a research collaboration with Takeda Pharmaceuticals to study the ability of movement disorders compound, PBT434 to slow or prevent neurodegeneration of the gastrointestinal system.
    Catalyst Biosciences, Inc. (NASDAQ: CBIO) rose 10.49 percent to $7.90 as the company announced the appointment of Arwa Shurrab and Jamie Ellen Siegel in its clinical hemophilia

  • [By Lisa Levin]

    Shares of Vince Holding Corp (NYSE: VNCE) were down around 15 percent to $3.67. Vince Holding projects full-year sales and EPS to come in at or below the low end of its earlier issued outlook.

  • [By Lisa Levin]

    Shares of Vince Holding Corp (NYSE: VNCE) were down around 41 percent to $0.800. Vince Holding reported a Q4 loss of $162.1 million on revenue of $63.9 million.

  • [By Peter Graham]

    Small cap upscale apparel brandretailer Vince Holding Corp (NYSE: VNCE) reported Q1 2017 financial results before the market opened this morning. Net sales decreased 14.2% to $58.0 million as wholesale segment sales decreased 20.9% to $35.4 million, primarily due to a reduction in full-price orders as a result of the elimination of the Companys summer delivery, and asdirect-to-consumer segment salesfell 1.0% to $22.6 million. Comparable sales decreased 5.7%, including e-commerce sales, due to a decrease in average order value.

Top 10 Casino Stocks To Watch Right Now: Edwards Lifesciences Corporation(EW)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Shares of Edwards Lifesciences (EW) jumped to the top of the S&P 500 today after the medical-device maker offered its 2017 guidance this morning at its investor day.

    Getty Images

    Shares of Edwards Lifesciences gained 6.7% to $89.31 today, while the S&P 500 rose 0.2% to 2,246.19.

    Wells Fargo’sLarry Biegelsen offers his take on Edwards Lifesciences’ guidance:

    Edwards Lifesciences Corporation (EW-$83.73; Outperform) provided its 2017 outlook this morning (12/8) ahead of its investor meeting today. As expected, the company highlighted its robust pipeline which should drive strong growth for years to come. However, the company now expects Q4 16 revenue to come in at the low end of the guidance range due to currency and weakness in surgical heart valves. The 2017 guidance was generally strong on the top and bottom line, with both bracketing consensus.

    For 2017, EW expects sales of $3.0-3.4B and 10-14% underlying growth. This compares to consensus of $3.3B and 12.3% underlying growth (were at 12.6%)… For 2017 EPS, EW expects $3.30-3.45 which includes $0.10 dilution from the Valtech deal (something we highlighted in our preview) and $0.08-0.10 benefit from the accounting change for stock based compensation. Backing these two items out implies guidance of about $3.30-3.45 which compares to consensus of $3.40 and our estimate of $3.41…

    As expected, the pipeline updates were highly positive. While the initial reaction to the Q4 guidance will likely be negative, we are highly confident that the strong 2017 guidance and robust pipeline update will be the main takeaways from the meeting today.

    No negativity here: Edwards Lifesciences’ market capitalization rose to $19.1 billion today from $17.9 billion yesterday. It reported net income of $495 million on sales of $2.5 billion in 2015.

  • [By ]

    In the Lightning Round, Cramer was bullish on Align Technology (ALGN) , Regions Financial (RF) , Edwards Lifesciences (EW) , Qualys (QLYS) and HEICO (HEI) .

  • [By Ben Levisohn]

    Edwards Lifesciences (EW) soared to the top of the S&P 500 today after the medical-device company beat earnings and revenue forecasts, and raised its full-year guidance.

    Getty Images

    Edwards Lifesciencesgained 11% to 109.33, while the S&P 500 dipped 0.1% to 2,387.45.

    Mogran Stanley’s David Lewis andScott Wang contend that that Edwards Lifesciences is “back on track.” They explain:

    US sequential acceleration returns to the prior curve and debunks the bear case. Sequential growth in US [transcatheter aortic valve replacement, or TAVR,] in 1Q17 was ~12%, more in line with the ~13.5% average growth rate seen in the five quarters leading up to 3Q16. It’s hard to pinpoint the drivers, but we see several dynamics, including: (i) underlying device utilization thus far in 1Q, (ii) faster ramp at new hospitals where one additional TAVR per center is worth $15mn (~65% of the US upside we saw this quarter), and (iii) less acute competitive pressure from Medtronic (MDT) on larger valve sizes. SURTAVI likely played a limited role but management did not rule it out. Guidance implies a more conservative q/q US growth of ~3% for the rest of the year vs the ~12% this quarter, but underlying strength in the quarter is a material shift in US growth and intermediate penetration. As we stated in our preview, we favored the risk reward into the quarter given achievable expectations and the >20 point lag vs Intuitive YTD and would expect significant recovery tomorrow. Momentum likely continues into 2Q17 as signs of improving intermediate risk penetration provide important offsets to increased competition from Boston in early-2018 before mitral takes hold.

    Edwards Lifesciences’ market capitalization rose to $23.1 billion today from $20.9 billion yesterday.

  • [By ]

    Edwards Lifesciences (EW) : “They have the best devices. That stock is a buy.”

    Align Technology (ALGN) : “The stock is breaking down. Let’s wait a few days then pull the trigger.”

  • [By Lisa Levin]

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

    Edwards Lifesciences Corp (NYSE: EW) reported better-than-expected results for its first quarter, but issued weak earnings guidance for the second quarter. Edwards Lifesciences shares tumbled 7.80 percent to $124.17 in the after-hour

  • [By Stephan Byrd]

    Westpac Banking Corp raised its stake in Edwards Lifesciences (NYSE:EW) by 22.6% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 67,689 shares of the medical research company’s stock after purchasing an additional 12,500 shares during the period. Westpac Banking Corp’s holdings in Edwards Lifesciences were worth $9,444,000 as of its most recent SEC filing.

Top 10 Casino Stocks To Watch Right Now: TripAdvisor, Inc.(TRIP)

Advisors’ Opinion:

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Tuesday was TripAdvisor, Inc. (NASDAQ: TRIP) which rose over 4% to $44.55. The stocks 52-week range is $35.34 to $66.13. Volume was 2.8 million compared to its average volume of 2.9 million.

  • [By Paul Ausick]

    TripAdvisor Inc. (NASDAQ: TRIP) dropped about 4.5% Thursday, to post a new 52-week low of $43.48 after closing at $45.55 on Wednesday. The stock’s 52-week high is $71.69. Volume was about 60% above the daily average of around 2.4 million shares. The company had no specific news today.

  • [By Peter Graham]

    A long term performance chart shows Angie’s List basically back to breakeven while other online review stocks like small cap Yelp Inc (NYSE: YELP) and mid cap Tripadvisor Inc (NASDAQ: TRIP) have performed a bit better with mid capacquirer IAC has been a better performer:

  • [By Jeremy Bowman]

    Shares ofTripadvisor Inc(NASDAQ:TRIP) were heading lower today, falling in sympathy withTrivago(NASDAQ:TRVG)after shares of the hotel-booking platform crashed 24% when the company recorded a decline in first-quarter revenue and cut its guidance for the year. Though there was no direct news out on Tripadvisor today, shares of the travel-recommendation service nonetheless finished down 8.5% today as it is subject to many of the same business trends as Trivago in the online travel industry.

Top 10 Casino Stocks To Watch Right Now: Integrated Device Technology, Inc.(IDTI)

Advisors’ Opinion:

  • [By Lisa Levin]

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

    Analysts are expecting Discovery Communications Inc. (NASDAQ: DISCA) to have earned $0.47 per share on revenue of $1.69 billion in the latest quarter. Discovery Communications shares rose 0.17 percent to $29.08 in after-hours trading.
    Analysts expect T-Mobile US Inc (NASDAQ: TMUS) to report

  • [By Lisa Levin]

     

    T-Mobile US Inc (NYSE: TMUS) reported upbeat earnings for its fourth quarter on Tuesday.
    Integrated Device Technology Inc (NASDAQ: IDTI) agreed to acquire GigPeak Inc (NYSE: GIG) for around $250 million in cash.
    Charles River Laboratories Intl. Inc (NYSE: CRL) reported better-than-expected profit for its fourth quarter.
    Amkor Technology, Inc. (NASDAQ: AMKR) posted downbeat revenue for its fourth quarter and issued a weak outlook for the current quarter.

Hot Casino Stocks To Invest In 2018

Officials in China’s gambling enclave of Macau have raised concerns about sexual misconduct allegations against casino mogul Steve Wynn.

The intervention adds to mounting pressure on Wynn and Wynn Macau (WYNMF), the business that generates most of the profit for his gambling empire. The Hong Kong-listed division of Wynn Resorts (WYNN) has lost more than $2 billion in stock market value over the past two days.

The plunge comes after a Wall Street Journal investigation uncovered decades of sexual misconduct allegations made against Wynn, the 76-year-old founder and CEO of Wynn Resorts. The company’s board of directors has launched an investigation into the allegations, which Wynn has denied.

In a statement Tuesday, Macau’s Gaming Inspection and Coordination Bureau said it had expressed concern about reports of Wynn’s “involvement in inappropriate behavior” during a meeting with Wynn Macau’s leadership. It said it has asked the company for more information.

Hot Casino Stocks To Invest In 2018: Teladoc, Inc.(TDOC)

Advisors’ Opinion:

  • [By Steve Symington, Rich Smith, and Keith Speights]

    But from an investor’s perspective, that raises the question: Are there other stocks that could offer similar returns?So we asked three top Motley Fool contributors to each pick a stock they believe hasNVIDIA-like return potential. Read on to see why they chose CalAmp (NASDAQ:CAMP), Kratos Defense & Security (NASDAQ:KTOS), and Teladoc (NYSE:TDOC).

  • [By Chris Hill]

    In today’s episode of MarketFoolery, host Chris Hill and Motley Fool analyst Jason Moser go through some of the messy metrics from this quarter and explain which areas long-term investors should focus on to track how the company is doing. Also, Texas Roadhouse(NASDAQ:TXRH) clocked in another good quarter, but how can the restaurant grow from here? Virtual healthcare provider Teladoc (NYSE:TDOC)reports earnings later today, and long-term investors should watch for progress in these key metrics. Tune in to find out more.

  • [By Keith Speights]

    CVS Health isn’t starting from scratch in developing its virtual care services, though. Merlo stated that the company is partnering with telehealth leaderTeladoc (NYSE:TDOC). He said CVS will use Teladoc as the engine to provides telehealth services through CVS Health’s app. The services will be provided by the company’s MinuteClinic as well as other providers. Merlo added that Teladoc is basically “private labeling our telehealth program.”

Hot Casino Stocks To Invest In 2018: Advantage Lithium Corp. (AVLIF)

Advisors’ Opinion:

  • [By ]

    Advantage Lithium (OTCQX:AVLIF) is a strategic advanced junior lithium exploration company that operates between Lithium Americas and Orocobre in the Cauchari-Olaroz basin. Orocobre is the largest shareholder in the company with a 30% equity stake, coupled with a 25% interest in the project. Over the past few months, the company has been moving towards completing the second stage of its drilling campaign, which will be completed in May 2018 and will then be followed on with an updated Natural Resource Estimate Study. This will allow the company to move into phase three of its drilling efforts, which will utilize larger drills to further define the resource, with a Feasibility Study expected to be completed in the first part of 2019.

  • [By SEEKINGALPHA.COM]

    The other producing lithium miners, and soon to be producers. I have discussed these previously in detail here, here and here. Needless to say, the top 3 producers are non-pure plays (SQM (NYSE:SQM), Albemarle (NYSE:ALB), and FMC Corp. (NYSE:FMC)). The top pure play currently producing miners are Orocobre (ASX:ORE) (OTCPK:OROCF), Tianqi Lithium (SHE:002466), Jiangxi Ganfeng Lithium, Galaxy Resources, Mineral Resources [ASX:MIN] (OTC:MALRF), and Neometals [ASX:NMT] (OTC:RRSSF). The near-term producers include Altura Mining [ASX:AJM] (OTCPK:ALTAF), Pilbara Minerals (ASX:PLS) (OTC:PILBF), Kidman Resources (ASX:KDR), Critical Elements, Nemaska Lithium (OTCQX:NMKEF) [TSX:NMX], Lithium Americas (OTCQX:LACDF) [TSX:LAC], Lithium X (OTCQX:LIXXF) (TSXV:LIX), Neo Lithium, and Bacanora Minerals (OTC:BCRMF) [TSXV:BCN], Advantage Lithium (OTCQB:AVLIF) [AAL], European Metals (OTCPK:MNTCF, ASX:EMH, AIM:EMH) and Pure Energy (OTCQB:PEMIF) [PE].

Hot Casino Stocks To Invest In 2018: Stag Industrial, Inc.(STAG)

Advisors’ Opinion:

  • [By Lee Jackson]

    STAG Industrial Inc. (NYSE: STAG) offers investors a 5.8% yield. Share recently traded hands at $24.35 apiece, in a 52-week range of $22.42 to $28.85. The consensus target price is $27.73.

Hot Casino Stocks To Invest In 2018: Advantage Oil & Gas Ltd(AAV)

Advisors’ Opinion:

  • [By Max Byerly]

    Advantage Oil & Gas (NYSE:AAV) (TSE:AAV) released its quarterly earnings data on Thursday. The oil and gas company reported $0.04 EPS for the quarter, missing the Zacks’ consensus estimate of $0.07 by ($0.03), MarketWatch Earnings reports. The business had revenue of $58.07 million during the quarter, compared to analyst estimates of $62.09 million. Advantage Oil & Gas had a net margin of 39.22% and a return on equity of 2.98%.

Hot Casino Stocks To Invest In 2018: Cellectis S.A.(CLLS)

Advisors’ Opinion:

  • [By Jim Robertson]

    Yesterday, small cap clinical-stage biopharmaceutical stock Cellectis SA (NASDAQ: CLLS) reported that they had received notice fromFDA that a clinical hold was placed on both UCART123 ongoing Phase 1 studies -in acute myeloid leukemia (AML) and in blastic plasmacytoid dendritic cell neoplasm (BPDCN). The clinical hold was initiated after Cellectis reported one fatality in the BPDCN clinical trial (ABC study) with the Company now working closelywith the investigators and the FDA in order to resume the trials with an amended protocol including a lowered dosing of UCART123. The FDA has a detailed page about clinical holds which mentions:

  • [By Lisa Levin]

    Cellectis SA (ADR) (NASDAQ: CLLS) shares dropped 20 percent to $25.70 after announcing FDA clinical hold of UCART123 studies.

    Shares of Opiant Pharmaceuticals Inc (NASDAQ: OPNT) were down 10 percent to $35.20. Opiant Pharma named David O'Toole as CFO.

Top Warren Buffett Stocks To Own For 2019

&l;!–donotpaginate–&g;&l;p&g;When investing, sometimes the best way to make money in the stock market over time is to do nothing. Just invest passively.

That&s;s what &l;a href=&q;https://www.entrepreneur.com/article/306846&q; target=&q;_blank&q;&g;Warren Buffett did in making a $1 million bet&l;/a&g; that he could do better than a portfolio of hedge funds. Did the Oracle of Omaha find some great, bargain-priced stocks? Did he make the deal of the century by finding an emerging tech company?

Nope. He simply said that by investing in a boring, low-cost stock index fund you could outperform most hedge funds over the past decade. He made no new investments and didn&s;t time the 2008 market crash. He just stayed put in an index fund.

How clever is that? Well, it requires no investing skill, although when you do the math, it&s;s brilliant. By just riding the tide of the stock market — and not timing it — you do much better than guessing when to jump in and out. Research proves this works most of the time.

Top Warren Buffett Stocks To Own For 2019: Care.com, Inc.(CRCM)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Care.com Inc (NYSE: CRCM) got a boost, shooting up 16 percent to $11.01 after the company reported upbeat quarterly results.

    MaxPoint Interactive Inc (NASDAQ: MXPT) shares were also up, gaining 19 percent to $5.44. MaxPoint Interactive reported Q4 earnings of $0.59 per share on revenue of $46.3 million.

Top Warren Buffett Stocks To Own For 2019: Eagle Bancorp, Inc.(EGBN)

Advisors’ Opinion:

  • [By Paul Ausick]

    Eagle Bancorp Inc. (NASDAQ: EGBN) dropped 28% Friday to post a new 52-week low of $47.65 after closing at $66.15 on Thursday. The stock’s 52-week high is $69.80. Volume of around 3.6 million was more than three times the daily average. The bank holding company had no specific news Friday.

  • [By Lisa Levin]

    On Monday, the financial sector proved to be a source of strength for the market. Leading the sector was strength from Eagle Bancorp, Inc. (NASDAQ: EGBN) and BankUnited (NYSE: BKU).

Top Warren Buffett Stocks To Own For 2019: vTv Therapeutics Inc.(VTVT)

Advisors’ Opinion:

  • [By Stephan Byrd]

    COPYRIGHT VIOLATION NOTICE: “Q1 2018 EPS Estimates for vTv Therapeutics Decreased by Seaport Global Securities (VTVT)” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.tickerreport.com/banking-finance/3350631/q1-2018-eps-estimates-for-vtv-therapeutics-decreased-by-seaport-global-securities-vtvt.html.

  • [By Paul Ausick]

    vTv Therapeutics Inc. (NASDAQ: VTVT) dropped about 79% Tuesday to post a new 52-week low of $0.69. Shares closed at $3.26 on Monday and the stock’s 52-week high is $8.40. Volume was about 30 times the daily average of around 205,000 shares. The company’s Alzheimer drug failed to meet the goals of a phase 3 study.

  • [By Paul Ausick]

    vTv Therapeutics Inc. (NASDAQ: VTVT) dropped about 8.5% Wednesday to post a new 52-week low of $0.65. Shares closed at $0.71 on Tuesday and the stock’s 52-week high is $8.40. Volume was about 7 times the daily average of around 340,000 shares. The company’s Alzheimer drug failed Tuesday to meet the goals of a phase 3 study and the sell-off continues.

Top Warren Buffett Stocks To Own For 2019: Cellectis S.A.(CLLS)

Advisors’ Opinion:

  • [By Lisa Levin]

    Cellectis SA (ADR) (NASDAQ: CLLS) shares dropped 20 percent to $25.70 after announcing FDA clinical hold of UCART123 studies.

    Shares of Opiant Pharmaceuticals Inc (NASDAQ: OPNT) were down 10 percent to $35.20. Opiant Pharma named David O'Toole as CFO.

  • [By Jim Robertson]

    Yesterday, small cap clinical-stage biopharmaceutical stock Cellectis SA (NASDAQ: CLLS) reported that they had received notice fromFDA that a clinical hold was placed on both UCART123 ongoing Phase 1 studies -in acute myeloid leukemia (AML) and in blastic plasmacytoid dendritic cell neoplasm (BPDCN). The clinical hold was initiated after Cellectis reported one fatality in the BPDCN clinical trial (ABC study) with the Company now working closelywith the investigators and the FDA in order to resume the trials with an amended protocol including a lowered dosing of UCART123. The FDA has a detailed page about clinical holds which mentions: